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Summary:
•

•

The current guidelines for patient’s living with HIV is to screen for anal
dysplasia with an annual digital anorectal screen (dare) for all patients
≥35 years old and those <35 with symptoms of anal cancer. This is done
with an Anal Papanicolaou with cytology.
A baseline test should be obtained, and if normal be performed annually
thereafter. Currently, at Truman clinic, among the infectious disease
fellow physicians, there is only 8% adherence rate to anal pap screening.
This project will focus on improving education and anal pap screening in
this population.

Results:
• From April 1, 2021 to May 18, 2021, 11 patient's fit criteria for screening,
and were given information and the option for Self vs. Clinician collection.
• 8 of the 11 patient's completed an Anal Pap, 3 of which were Self
collection.
• This improved adherence in 2 months from 8 to 29.7 %
• 1 patient was found to have HGSIL, was referred for HRA

Introduction:
•

•
•
•
•
•

Anal cancer is a squamous cell cancer associated with human
papillomavirus (HPV), the same virus that is associated with cervical
cancer.
In HIV-infected men and women, the incidence is higher of anal cancer
than in the general population.
An anal Papanicolaou is a simple test which detects abnormal cells which
that may be a possible precursor of anal cancer, and can determine need
for referral for HRA and further intervention
The anal pap can be done by a clinician, or by the patient via self
collection.
Studies have shown that anal self-sampling and accuracy was similar to
that of clinician sampled specimens.
In addition to providing educational materials, to determine if there is an
improvement in adherence to screening guidelines, patient’s will be
offered both self collection vs. clinician collection Anal Papanicolaou.

Methods:
• Patient’s included: All HIV positive patient’s >35 years old, or those <35
who have anal cancer symptoms on the Fellow Physician clinic panel.
• Baseline data obtained indicated 8.5% of patient’s have been
appropriately screened before April 1, 2021.
• As of April 1, 2021, each clinic session, the medical assistant will report on
all patient’s due for anal pap screening, patient’s will be provided info
pamphlet, including rational of screening and steps if screening is
abnormal.
• Fellow will offer provider or self collect option in clinic room. If self pap is
selected, tutorial on proper technique will be given.
• If patient declines, symptom screening will be done and chart note to
offer next visit
• Documentation will be done on anal cancer screening and discussion and
intervention (when applicable) will be placed in EMR at least annually.

Discussion:
•

•

•
•
•

Anal cancer is a squamous cell cancer associated with human
papillomavirus (HPV), the same virus that is associated with cervical
cancer. Although vaccination against HPV has been shown to be effective
in reducing overall rates of infection [1], the number of new anal cancer
cases has been rising for many years.
Research has shown barriers anal cancer screening include a lack of
awareness of HPV, stigma associated with anal Pap testing, psychological
discomfort associated with anal Pap testing, the idea that the anus is
hidden or private, HIV as an overriding concern, and general reluctance
among men to seek health care.
This project was meant to aid in bringing awareness to HPV, reducing the
psychological discomfort associated with Anal testing, and providing the
option of keeping the anus a private part of the patient's body if desired,
After applying the intervention, we increased the adherence of Anal Pap's
within the clinic panel to 29.7%.
Limitations include not knowing what the best intervention was, limited
period of time data was collected.

Next steps:
•
•
•
•
•
•

Continue offering Self vs. Clinician anal pap until fellow panel completed.
Upon completion consider a survey to assess what intervention made the
most difference.
Roll out to other provider's at Truman clinic
Compare sampling of provider collect versus Patient collected samples
Determine rate of abnormal Anal Pap among Truman Clinic patient
population
For those who qualify for HRA determine rate of adherence post
intervention versus prior.
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